Carnegie Capital Asset Management, LLC Iovance Biotherapeutics, Inc. Transaction History
Carnegie Capital Asset Management, LLC
- $3.34 Billion
- Q3 2024
A detailed history of Carnegie Capital Asset Management, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 27,000 shares of IOVA stock, worth $250,290. This represents 0.01% of its overall portfolio holdings.
Number of Shares
27,000
Previous 27,000
-0.0%
Holding current value
$250,290
Previous $216,000
17.13%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding IOVA
# of Institutions
314Shares Held
241MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$253 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$247 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$222 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$197 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$122 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.46B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...